PHILIP SANGSTER: Open Payments
NPI 1801405758 · ATLANTA, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$4,048 in 167 payments from 21 companies in 2025. Trend: 2023 $1,490 · 2024 $3,428 · 2025 $4,048
Food & beverage: $3,196Travel & lodging: $848Education: $5
| Company | Payments | Amount |
|---|---|---|
| Brainsway USA INC | 1 | $848 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 30 | $458 |
| Neurocrine BioSciences, Inc. | 16 | $324 |
| Alkermes, Inc. | 12 | $274 |
| Otsuka America Pharmaceutical, Inc. | 13 | $262 |
| Lundbeck LLC | 12 | $231 |
| Vanda Pharmaceuticals Inc. | 9 | $218 |
| ABBVIE INC. | 16 | $195 |
| Tris Pharma Inc | 9 | $180 |
| Janssen Pharmaceuticals, Inc | 8 | $174 |
Products named: Deep Tms, CAPLYTA, INGREZZA, REXULTI, ARISTADA, ABILIFY ASIMTUFII, VRAYLAR, Dyanavel XR.
Industry payments across GA — which companies pay providers there.
